Lund-based cancer treatment company Lithea, developer of the LIT-platform – a technology enabling local treatment of solid tumours with an enhanced anti-cancer effect, recently announced that they have received a Certificate of Patent from the Japan Patent Office (JPO).
This means that the JPO has approved the patent application and registered the patent making it valid until 2041. This is the Company’s first patent to be granted in Japan for the LIT-platform technology.
“We are proud to announce that Lithea has secured patent approval in Japan. This milestone underscores our commitment to innovation and strengthens our position in delivering cutting-edge intratumoral therapies to patients worldwide. It also underscores our organization’s ability to generate patentable inventions.”
says Ludvig Sjöberg, CEO of Lithea
The patent provides the LIT-platform protection for treating cancer using the LIT-platform to deliver pharmaceutical drugs. Lithea has patents granted to date in Europe, Japan, and Singapore, with late-stage applications in the USA and China.
